{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:05:10Z","timestamp":1793160310597,"version":"4.5.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,6,22]]},"DOI":"10.1001\/jama.2021.7517","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T15:34:04Z","timestamp":1619796844000},"page":"2448","source":"Crossref","is-referenced-by-count":491,"title":["US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021"],"prefix":"10.1001","volume":"325","author":[{"given":"Isaac","family":"See","sequence":"first","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Su","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Lale","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Jane","family":"Woo","sequence":"additional","affiliation":[{"name":"Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Y.","family":"Guh","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom T.","family":"Shimabukuro","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Streiff","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agam K.","family":"Rao","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison P.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne F.","family":"Beavers","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna P.","family":"Durbin","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Edwards","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Miller","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Harrington","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adamma","family":"Mba-Jonas","sequence":"additional","affiliation":[{"name":"Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan","family":"Nair","sequence":"additional","affiliation":[{"name":"Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duong T.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawsar R.","family":"Talaat","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor C.","family":"Urrutia","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon C.","family":"Walker","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Buddy","family":"Creech","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Clark","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"DeStefano","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"Broder","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10267","key":"joi210051r6","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial.","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"joi210051r7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000509802","article-title":"Cerebral Venous Thrombosis: A Comprehensive Review.","volume":"83","author":"Idiculla","year":"2020","journal-title":"Eur Neurol"},{"issue":"23","key":"joi210051r8","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1182\/blood-2014-01-549741","article-title":"Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder.","volume":"123","author":"Warkentin","year":"2014","journal-title":"Blood"},{"key":"joi210051r9","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"joi210051r10","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"joi210051r11","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCov-19 vaccination.","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"joi210051r13","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination.","author":"Muir","year":"2021","journal-title":"N Engl J Med"},{"key":"joi210051r15","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7018e2","article-title":"Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine\u2014United States, March\u2013April 2021.","author":"Shay","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"joi210051r16","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7017e4","article-title":"Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients\u2014United States, April 2021.","author":"MacNeil","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"joi210051r19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.15585\/mmwr.mm7015e2","article-title":"Trends in racial and ethnic disparities in COVID-19 hospitalizations, by region\u2014United States, March-December 2020.","volume":"70","author":"Romano","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"joi210051r20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/JBM.S232648","article-title":"Current perspectives on diagnostic assays and anti-PF4 antibodies for the diagnosis of heparin-induced thrombocytopenia.","volume":"11","author":"Sahu","year":"2020","journal-title":"J Blood Med"},{"issue":"4","key":"joi210051r21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3390\/molecules22040617","article-title":"Functional assays in the diagnosis of heparin-induced thrombocytopenia: a review.","volume":"22","author":"Minet","year":"2017","journal-title":"Molecules"},{"issue":"1","key":"joi210051r22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1182\/asheducation-2016.1.262","article-title":"Heparin-induced thrombocytopenia: research and clinical updates.","volume":"2016","author":"Onwuemene","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"joi210051r24","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1111\/jth.2017.15.issue-11","article-title":"Autoimmune heparin-induced thrombocytopenia.","volume":"15","author":"Greinacher","year":"2017","journal-title":"J Thromb Haemost"},{"key":"joi210051r25","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2106075","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination: response from the manufacturer.","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"joi210051r26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105412","article-title":"Cerebral venous sinus thromboses in patients with SARS-CoV-2 infection: three cases and a review of the literature.","volume":"29","author":"Nwajei","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"4","key":"joi210051r29","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1161\/STR.0b013e31820a8364","article-title":"Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"42","author":"Saposnik","year":"2011","journal-title":"Stroke"},{"issue":"1","key":"joi210051r31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/jnnp.70.1.105","article-title":"Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients.","volume":"70","author":"de Bruijn","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"joi210051r1","unstructured":"US Food and Drug Administration. Janssen COVID-19 vaccine. Accessed April 17, 2021. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/janssen-covid-19-vaccine"},{"key":"joi210051r2","unstructured":"CDC Health Alert Network. Cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson & Johnson COVID-19 vaccine. Accessed April 17, 2021. https:\/\/emergency.cdc.gov\/han\/2021\/han00442.asp?"},{"key":"joi210051r3","unstructured":"Centers for Disease Control and Prevention. COVID Data Tracker: COVID-19 vaccinations in the United States. Accessed April 17, 2021. https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations?"},{"key":"joi210051r4","unstructured":"European Medicines Agency. COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. Accessed April 20, 2021. https:\/\/www.ema.europa.eu\/en\/news\/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots?"},{"key":"joi210051r5","unstructured":"World Health Organization. Global Advisory Committee on Vaccine Safety (GACVS) review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 Vaccine (Vaxzevria and Covishield). Accessed April 24, 2021. https:\/\/www.who.int\/news\/item\/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-(vaxzevria-and-covishield)?"},{"key":"joi210051r12","unstructured":"Food and Drug Administration. FDA Briefing Document: Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting. February 26, 2021. Accessed April 27, 2021. https:\/\/www.fda.gov\/media\/146217\/download"},{"key":"joi210051r14","unstructured":"Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine. April 13, 2021. Accessed April 19, 2021. https:\/\/www.cdc.gov\/media\/releases\/2021\/s0413-JJ-vaccine.html"},{"key":"joi210051r17","unstructured":"Centers for Disease Control and Prevention. Clinical Immunization Safety Assessment (CISA) Project. Accessed April 24, 2021. https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/cisa\/index.html"},{"key":"joi210051r18","unstructured":"Brighton Collaboration. Interim case definition of thrombosis with thrombocytopenia syndrome. Accessed April 25, 2021. https:\/\/brightoncollaboration.us\/thrombosis-with-thrombocytopenia-syndrome-interim-case-definition\/?"},{"key":"joi210051r23","unstructured":"Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers). The Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Accessed April 24, 2021. https:\/\/www.fda.gov\/media\/146304\/download?"},{"key":"joi210051r27","unstructured":"CDC. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. Updated April 27, 2021. Accessed April 28, 2021. https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/clinical-considerations.html"},{"key":"joi210051r28","unstructured":"American Society of Hematology. Vaccine-induced immune thrombotic thrombocytopenia: frequently asked questions. Accessed April 17, 2021. https:\/\/www.hematology.org\/covid-19\/vaccine-induced-immune-thrombotic-thrombocytopenia"},{"key":"joi210051r30","unstructured":"American Heart Association. CVST and blood clots potentially related to the J&J COVID-19 vaccine: know the symptoms. Accessed April 25, 2021. https:\/\/newsroom.heart.org\/news\/cvst-and-blood-clots-potentially-related-to-the-j-j-covid-19-vaccine-know-the-symptoms?"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2779731\/jama_see_2021_oi_210051_1624316948.99561.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T16:06:40Z","timestamp":1624378000000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2779731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":31,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,6,22]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.7517","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}